Clinical relevance of the small intestine as an organ of drug elimination: Drug - fruit juice interactions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 1, 2007, Pages 67-80

  Paine, Mary F ^a   Oberlies, Nicholas H ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

Cranberry; CYP3A; Drug diet interactions; Drug fruit juice interactions; First pass metabolism; Furanocoumarins; Grapefruit; Natural product; Oral bioavailability; Pomegranate

Indexed keywords

6',7' DIHYDROXYBERGAMOTTIN; ANTIINFECTIVE AGENT; BERGAMOTTIN; CARBAMAZEPINE; CELIPROLOL; CYCLOSPORIN; CYTOCHROME P450 3A; DOCETAXEL; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FELODIPINE; FEXOFENADINE; FLAVONOID; FLURBIPROFEN; FUROCOUMARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; ORGANIC ANION TRANSPORTER; PACLITAXEL; PRAVASTATIN; RAPAMYCIN; RITONAVIR; SAQUINAVIR; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XENOBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; CRANBERRY JUICE; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; FIRST PASS EFFECT; FOOD COMPOSITION; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; IC 50; INTESTINE ABSORPTION; LIVER METABOLISM; LONG TERM CARE; NONHUMAN; ORANGE JUICE; ORTHOSTATIC HYPOTENSION; POLYPHARMACY; POMEGRANATE; PUMMELO; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; SMALL INTESTINE; SOUR ORANGE; STOMACH EMPTYING; SWEET ORANGE; URINARY TRACT INFECTION; ANIMAL; BEVERAGE; BIOLOGICAL MODEL; GRAPEFRUIT; METABOLISM; PROGNOSIS;

CITRUS X PARADISI; LYTHRACEAE; VACCINIUM MACROCARPON;

ANIMALS; BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINE, SMALL; MODELS, BIOLOGICAL; PROGNOSIS;

EID: 34249875093     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.1.67     Document Type: Review

References (107)

1. LIN JH, LU AY: Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Ann. Rev. Pharmacol. Toxicol. (2001) 41:535-567.
2. LAMBA JK, LIN YS, SCHUETZ EG, THUMMEL KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. (2002) 54:1271-1294.
3. WOJNOWSKI L: Genetics of the variable expression of CYP3A in humans. Ther. Drug Monit. (2004) 26:192-199.
4. PAINE MF, HART HL, LUDINGTON SS et al.: The human intestinal cytochrome P450 'pie'. Drug Metab. Dispos. (2006) 34:880-886.
5. KHANNA R, MORTON CL, DANKS MK, POTTER PM: Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res. (2000) 60:4725-4728.
6. FISHER MB, PAINE MF, STRELEVITZ TJ, WRIGHTON SA: The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. (2001) 33:273-297.
7. GLATT H, BOEING H, ENGELKE CE et al.: Human cytosolic sulphotransferases: genetics, characteristics, toxicological aspects. Mutat. Res. (2001) 482:27-40.
8. PACIFICI GM: Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: a review of the literature. Int. J. Clin. Pharmacol. Ther. (2004) 42:488-495.
9. GREGORY PA, LEWINSKY RH, GARDNER-STEPHEN DA, MACKENZIE PI: Regulation of UDP glucuronosyltransferases in the gastrointestinal tract. Toxicol. Appl. Pharmacol. (2004) 199:354-363.
10. POND SM, TOZER TN: First-pass elimination. Basic concepts and clinical consequences. Clin. Pharmacokinet. (1984) 9:1-25.
11. HELLRIEGEL ET, BJORNSSON TD, HAUCK WW: Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin. Pharmacol. Ther. (1996) 60:601-607.
12. GEORGE CF: Drug metabolism by the gastrointestinal mucosa. Clin. Pharmacokinet. (1981) 6:259-274.
13. WILLIAMS BR, KIM J: Medication use and prescribing considerations for elderly patients. Dent. Clin. North Am. (2005) 49:411-427.
14. FURLER MD, EINARSON TR, WALMSLEY S, MILLSON M, BENDAYAN R: Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS (2004) 18:568-586.
15. BLOWER P, DE WIT R, GOODIN S, AAPRO M: Drug-drug interactions in oncology: why are they important and can they be minimized? Crit. Rev. Oncol. Hematol. (2005) 55:117-142.
16. WILKINSON GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. (2005) 352:2211-2221.
17. DRESSER GK, BAILEY DG: The effects of fruit juices on drug disposition: a new model for drug interactions. Eur. J. Clin. Invest. (2003) 33(Suppl. 2):10-16.
18. EVANS AM: Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit. (2000) 22:131-136.
19. HARRIS RZ, JANG GR, TSUNODA S: Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. (2003) 42:1071-1088.
20. BAILEY DG, SPENCE JD, EDGAR B, BAYLIFF CD, ARNOLD JM: Ethanol enhances the hemodynamic effects of felodipine. Clin. Investig. Med. (1989) 12:357-362.
21. BAILEY DG, SPENCE JD, MUNOZ C, ARNOLD JM: Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337:268-269.
22. BAILEY DG, ARNOLD JMO, SPENCE JD: Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. (1998) 46:101-110.
23. WATKINS PB, WRIGHTON SA, SCHUETZ EG, MOLOWA DT, GUZELIAN PS: Identification of glucocorticoid-inducible cytochromes P450 in the intestinal mucosa of rats and man. J. Clin. Invest. (1987) 80:1029-1036.
24. PAINE MF, KHALIGHI M, FISHER JM et al.: Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. (1997) 283:1552-1562.
25. KANE GC, LIPSKY JJ: Drug-grapefruit juice interactions. Mayo Clin. Proc. (2000) 75:933-942.
26. LOWN KS, BAILEY DG, FONTANA RJ et al.: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. (1997) 99:2545-2553.
27. PAINE MF, CRISS AB, WATKINS PB: Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab. Dispos. (2004) 32:1146-1153.
28. GUO LQ, FUKUDA K, OHTA T. YAMAZOE Y. Role of furanocoumarin derivatives on grapefiuit juice-mediated inhibition of human CYP3A activity. Drug Metab. Dispos. (2000) 28:766-771.
29. TAKANAGA H, OHNISHI A, MATSUO H et al.: Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br. J. Clin. Pharmacol. (2000) 49:49-58.
30. TAKANAGA H, OHNISHI A, MURAKAMI H et al.: Relationship between time after intake of grapefiruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin. Pharmacol. Ther. (2000) 67:201-214.
31. GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS et al.: Time course of recovery of cytochrome P450 3A function after single doses of grapefruit juice. Clin. Pharmacol. Ther. (2003) 74:121-129.
32. MINISCALCO A, LUNDAHL J, REGARDH CG, EDGAR B, ERIKSSON UG: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapeftuit juice. J. Pharmacol. Exp. Ther. (1992) 261:1195-1199.
33. BAILEY DG, ARNOLD JM, STRONG HA, MUNOZ C, SPENCE JD: Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin. Pharmacol. Ther. (1993) 54:589-594.
34. BAILEY DG, ARNOLD JM, MUNOZ C, SPENCE JD: Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther. (1993) 53:637-642.
35. RASHID J, MCKINSTRY C, RENWICK AG et al.: Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. (1993) 36:460-463.
36. SCHMIEDLIN-REN P, EDWARDS DJ, FITZSIMMONS ME et al.: Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefiruir constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos (1997) 25:1228-1233.
37. HE K, IYER KR, HAYES RN et al.: Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. (1998) 11:252-259.
38. TASSANEEYAKUL W, GUO LQ, FUKUDA K, OHTA T, YAMAZOE Y: Inhibition selectivity of grapefiruit juice components on human cytochromes P450. Arch. Biochem. Biophys. (2000) 378:356-363.
39. FUKUDA K, OHTA T, OSHIMA Y et al.: Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics (1997) 7:391-396.
40. PAINE MF, CRISS AB, WATKINS PB: Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J. Pharmacol. Exp. Ther. (2005) 312:1151-1160.
41. BAILEY DG, DRESSER GK, BEND JR: Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin. Pharmacol. Ther. (2003) 73:529-537.
42. KAKAR SM, PAINE MF, STEWART PW, WATKINS PB: 6′7′-Dihydroxybergamottin contributes to the grapeftuit juice effect. Clin. Pharmacol. Ther. (2004) 75:569-579.
43. SCHWARZ UI, JOHNSTON PE, BAILEY DG et al.: Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br. J. Clin. Pharmacol. (2006) 62:485-491.
44. ROW E, BROWN SA, STACHULSKI AV, LENNARD MS: Development of novel furanocoumarin dimers as potent and selective inhibitors of CYP3A4. Drug Metab. Dispos. (2006) 34:324-330.
45. PAINE ME WIDMER WW, HART HL et al.: A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am. J. Clin. Nutr. (2006) 83:1097-1105.
46. DRESSER GK, BAILEY DG, LEAKE BF et al.: Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. (2002) 71:11-20.
47. XU J, GO ML, LIM LY. Modulation of digDxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit, and pummelo. Pharm. Res. (2003) 20:169-176.
48. SPAHN-LANGGUTH H, LANGGUTH P: Grapefruit juice enhances intestinal absorption of the P-glycoprorein substrate talinolol. Eur. J. Pharm. Sci. (2001) 12:361-367.
49. TAKANAGA H, OHNISHI A, MATSUO H, SAWADA Y: Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in Caco-2 cells. Biol. Pharm. Bull. (1998) 21:1062-1066.
50. OHNISHI A, MATSUO H, YAMADA S et al.: Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br. J. Pharmacol. (2000) 130:1369-1377.
51. HONDA Y, USHIGOME F, KOYABU N et al.: Effects of grapefruit juice and orange juice components on P-glycoprorein- and MRP2-mediated drug efflux. Br. J. Pharmacol. (2004) 143:856-864.
52. BECQUEMONT L. VERSTUYFT C, KERB R et al.: Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. (2001) 70:311-316.
53. PARKER RB, YATES CR, SOBERMAN JE, LAIZURE SC: Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy (2003) 23:979-987.
54. SCHWARZ UI, SEEMANN D, OERTEL R et al.: Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol. Ther. (2005) 77:291-301.
55. LILJA JJ, BACKMAN JT, LAITILA J, LUURILA H, NEUVONEN PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin. Pharmacol. Ther. (2003) 73:192-198.
56. KOBAYASHI D, NOZAWA T, IMAI K et al.: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-depcndent transport across intestinal apical membrane. J. Pharmacol. Exp. Ther. (2003) 306:703-708.
57. ITO K, SUZUKI H, HORIE T, SUGIYAMA Y: Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. (2005) 22:1559-1577.
58. CVETKOVIC M, LEAKE B, FROMM MF, WILKINSON GR, KIM RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. (1999) 27:866-871.
59. KULLAK-UBLICK GA, ISMAIR MG, STIEGER B et al.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology (2001) 120:525-533.
60. SATOH H, YAMASHITA F, TSUJIMOTO M et al.: Citrus juices inhibit the function of human organic anion-transporting polypepride OATP-B. Drug Metab. Dispos. (2005) 33:518-523.
61. KARCH AM: The grapeftuit challenge: the juice inhibits a crucial enzyme, with possibly fatal consequences. Am. J. Nurs. (2004) 104:33-35.
62. DREIER JP, ENDRES M: Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology (2004) 62:670.
63. ANDO H, TSURUOKA S, YANAGIHARA H et al.: Effects of grapefruit juice on the pharmacokinetics of Pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. (2005) 60:494-497.
64. LILJA JJ, KIVISTO KT, NEUVONEN PJ: Grapeftuit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. (1998) 64:477-483.
65. LILJA JJ, KIVISTO KT, NEUVONEN PJ: Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. (2000) 68:384-390.
66. KANTOLA T, KIVISTO KT, NEUVONEN PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. (1998) 63:397-402.
67. BAILEY DG, DRESSER GK: Interactions between grapefruit juice and cardiovascular drugs. Am. J. Cardiovasc. Drugs (2004) 4:281-297.
68. PAINE MF, LUDINGTON SS, CHEN ML et al.: Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab. Dispos. (2005) 33:426-433.
69. FUKUDA K, GUO L, ORASHI N, YOSHIKAWA M, YAMAZOE Y. Amounts and variation in grapefruit juice of the main components causing grapefruit--drug interaction. J. Chromatog. B Biomed. Sci. Appl. (2000) 741:195-203.
70. DE CASTRO WV, MERTENS-TALCOTT S, RUBNER A, BUTTERWECK V, DERENDORF H: Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J. Agric. Food Chem. (2006) 54:249-255.
71. MERTENS-TALCOTT SU, ZADEZENSKY I, DE CASTRO WV, DERENDORF H, BUTTERWECK V: Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol. (2006) 46:1390-1416.
72. MALHOTRA S, BAILEY DG, PAINE MF, WATKINS PB: Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocournarins. Clin. Pharmacol. Ther. (2001) 69:14-23.
73. EDWARDS DJ, FITZSIMMONS ME, SCHUETZ EG et al.: 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin. Pharmacol. Ther. (1999) 65:237-244.
74. MOULY SJ, MATHENY C, PAINE MF et al.: Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin. Pharmacol. Ther. (2005) 78:605-618.
75. KUPFERSCHMIDT HH, FATTINGER KE, HA HR, FOLLATH F, KRAHENBUHL S: Grapefruit juice enhances the bioavailability of the HIV prorease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. (1998) 45:355-359.
76. KROLL DJ, OBERLIES NH: The impact of newly proposed dietary supplement manufacturing guidelines on patient safety and clinical trials outcomes. Focus Altern. Compliment. Ther. (2003) 8:301-305.
77. PENZAK SR, ACOSTA EP, TURNER M et al.: Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J. Clin. Pharmacol. (2002) 42:1165-1170.
78. EGASHIRA K, OHTANI H, ITOH S et al.: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab. Dispos. (2004) 32:828-833.
79. EGASHIRA K, FUKUDA E, ONGA T et al.: Pomelo-induced increase in the blood level of cacrolimus in a renal transplant patient. Transplantation (2003) 75:1057.
80. GRENIER J, FRADETTE C, MORELLI G et al.: Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin. Pharmacol. Ther. (2006) 79:255-262.
81. YEE GC, STANLEY DI, PESSA LJ et al.: Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 345:955-956.
82. LILJA JJ, JUNTTI-PATINEN L, NEUVONEN PJ: Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin. Pharmacol. Ther. (2004) 75:184-190.
83. TAKANAGA H, OHNISHI A, YAMADA S et al.: Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther. (2000) 293:230-236.
84. KOITABASHI Y, KUMAI T, MATSUMOTO N et al.: Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci. (2006) 78:2852-2859.
85. SHITARA Y, SUGIYAMA Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. (2006) 112:71-105.
86. RAZ R, CHAZAN B, DAN M: Cranberry juice and urinary tract infection. Clin. Infect. Dis. (2004) 38:1413-1419.
87. FRANCO AV: Recurrent urinary tract infections. Best Pract. Res. Clin. Obstet. Gynaecol. (2005) 19:861-873.
88. MANGES AR, JOHNSON JR, FOXMAN B et al.: Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. (2001) 345:1007-1013.
89. HOWELL AB, FOXMAN B: Cranberry juice and adhesion of antibiotic-resistant uropathogens. JAMA (2002) 287:3082-3083.
90. HOWELL AB, VORSA N, DER MARDEROSIAN A, FOO LY: Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. N. Engl. J. Med. (1998) 339:1085-1086.
91. UESAWA Y, MOHRI K: Effects of cranberry juice on nifedipine pharmacokinetics in rats. J. Pharm. Pharmacol. (2006) 58:1067-1072.
92. ASTON JL, LODOLCE AE, SHAPIRO NL: Interaction between warfarin and cranberry juice. Pharmacotherapy (2006) 26:1314-1319.
93. SUVARNA R, PIRMOHAMED M, HENDERSON L: Possible interaction between warfarin and cranberry juice. Br. Med. J. (2003) 327:1454.
94. GREENBLATT DJ, VON MOLTKE LL, PERLOFF ES et al.: Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin. Pharmacol. Ther. (2006) 79:125-133.
95. PANTUCK AJ, LEPPERT JT, ZOMORODIAN N et al.: Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin. Cancer Res. (2006) 12:4018-4026.
96. AVIRAM M, ROSENBLAT M, GAITINI D et al.: Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin. Nutr. (2004) 23:423-433.
97. DE NIGRIS F, VALLIAMS-IGNARRO S, LERMAN LO et al.: Beneficial effects of pomegranate juice on oxidation-sensitive genes and endothelial nitric oxide synthase activity at sites of perturbed shear stress. Proc. Natl. Acad. Sci. USA (2005) 102:4896-4901.
98. GIL MI, TOMAS-BARBERAN FA, HESS-PIERCE B, HOLCROFT DM, KADER AA. Antioxidant activity of pomegranate juice and its relationship with phenolic composition and processing. J. Agric. Food Chem. (2000) 48:4581-4589.
99. HIDAKA M, OKUMURA M, FUJITA K et al.: Effects of pomegranate juice on human cyrochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab. Dispos. (2005) 33:644-648.
100. OWEN A, PIRMOHAMED M, TETTEY JN et al.: Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. (2001) 51:345-349.
101. MAINES LW, ANTONETTI DA, WOLPERT EB, SMITH CD: Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacol. (2005) 49:610-617.
102. SEERAM NR ZHANG Y, REED JD, KRUEGER CG, VAYA J: Pomegranate phytochemicals. In: Pomegranates: Ancient Roots to Modern Medicine. Seeram NP, Schulman RN, Heber D et al. (Eds), CRC Press, Boca Raton, FL, USA (2006):3-29.
103. EISENBERG DM, DAVIS RB, EYINER SL et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA (1998) 280:1569-1575.
104. GU ZM, ZHOU DW, LEWIS NJ et al.: Quantitative evaluation of annonaceous acetogenins in monthly samples of paw paw (Asimina triloba) twigs by liquid chromatography electrospray ionization tandem mass spectrometry. Phytochem. Anal. (1999) 10:32-38.
105. SANTOS-GOMES PC, FERNANDES-FERREIRA M: Organ- and season-dependent variation in the essential oil composition of Salvia officinalis L. cultivated at two different sites. J. Agric. Food Chem. (2001) 49:2908-2916.
106. RATNAYAKE S, RUPPRECHT JK, POTTER WM, MCLAUGHLIN JL: Evaluation of various parts of the paw paw tree, Asimina triloba (Annonaceae), as commercial sources of the pesticidal Annonaceous; acetogenins. J. Econ. Entomol. (1992) 85:2353-2356.
107. 1H NMR spectroscopy. J. Agric. Food Chem. (2001) 49:2687-2696.